Replies to post #79662 on NanoViricides Inc. (NNVC)

[another_voice_2]

I will let the BIG K answer these point by point.

[freethemice]

From the Jan 27th PR we know that the cGMP plant is not quite finished yet, and then testing and validation needs to be done. I would say quite a while yet before production begins. The schedule released called for phase 1 trial to begin in 2015.

"The Company reports that its project for enabling clinical scale drug product cGMP capability at the Shelton facility is now nearing completion of construction. After construction is complete, the facility, and particularly the cGMP Clean Room Suites will undergo facility testing and validation to ascertain that the facility satisfies the requirements. After validation, the Company plans to occupy the new facility while keeping the current facility active to minimize impact on the multiple nanoviricides® drug development projects. The Company intends to first start production of FluCide in the cGMP section, set up appropriate cGMP operation for this production, produce multiple batches of FluCide under cGMP conditions, and demonstrate equivalence of the batches produced, in preparation for human clinical trials."

[ZincFinger]

IMHO your expectations of disclosures are totally unrealistic for a high technology company. High technology is very competitive, most especially in biotechnology (one of the hottest sectors right now) and there are many things that are not discussed for very obvious competitive reasons (if one pauses to think).

I challenge you to name one single early stage biotech that reveals remotely as much detailed information as you are expecting here.

Unrealistic expectations can seriously impair ones investing success.

Giving projections with explicit timing is highly inadvisable for biotechs most especially (since the timing of events in biotechnology is inherently highly variable, far more so than other high technologies). Most biotechs give very approximate "guidance" (to emphasize that it's ONLY a rough guideline, not a "schedule" as to expected progress. Nevertheless all too many investors attach far too much significance to what are not even really deviations from such guidelines. (I followed one company that guided to CC "approximately in mid Month". When the 15th came and no CC some investors where howling about it being "overdue"

Frankly even most companies with very conventional technologies don't give out information in the kind of detail you are expecting. (I would suggest that you look up "micro-managing")